Important Updates on New Alzheimer's Drug

President & CEO Update

Alzheimer's Association

This message is sent to all Alzheimer's Association and Alzheimer's
Impact Movement board members, all Alzheimer's Association staff,
Zenith Society members and volunteers and supporters of AIM and the
Alzheimer's Association.

As you know, the Alzheimer's Association has advocated strongly
for approval of aducanumab, now called Aduhelm, which received
accelerated approval from the Food and Drug Administration (FDA) on
June 7. This treatment, while not a cure, has the potential to give
more time to those with Mild Cognitive Impairment (MCI) due to
Alzheimer's or those with early stage Alzheimer's
dementia.

Thanks to your strong support of our work in so many ways, this is the
first treatment ever to achieve such approval to address
Alzheimer's disease itself, not just the symptoms.

Since I last communicated with you about the approval, much has
happened. The FDA has now clarified the people who would likely
benefit from this new treatment. It is the same group I described
above and the group that the Alzheimer's Association has
advocated to have access to this treatment throughout the approval
process.

Achieving access to treatment for those who would likely benefit is
now our focus.

Regrettably, Biogen, the company that developed Aduhelm, priced it at
$56,000 annually. That is simply unacceptable. The Alzheimer's
Association continues to call on the company to change that price. To
fail to do so would deny access for many who could benefit.

To achieve access for this treatment, and other treatments that will
one day follow, the Alzheimer's Association is committed to
working with the Centers for Medicare & Medicaid Services (CMS), as
well as health insurance companies and others in the private payer
community, to expedite coverage and access.

You might have also heard that there have been multiple calls for
investigation of the approval process for Aduhelm. The
Alzheimer's Association strongly supports such inquiries to
reassure all of us that treatment approval processes work the way they
should.

We firmly believe that the FDA's accelerated approval was the
right decision, given the publicly available science, especially for
such a devastating and fatal disease - one that otherwise has no
treatment to even slow it down. Having the availability of such an
option and access to it are needs we've long heard from the
patient and caregiver community that we serve.

You can be assured that the Alzheimer's Association will
continue to advocate for coverage of this now approved treatment for
everyone who is likely to benefit.

Thank you so much for all of your support to make it possible to
improve the lives of so many others!

Sincerely,

Harry Johns Signature

Harry Johns
Chief Executive Officer

CONNECT WITH US

Facebook

Twitter

Pinterest

Blog

[link removed]
[link removed]
[link removed]
[link removed]

Alzheimer's Association

Alzheimer's Association

225 N. Michigan Ave., FL 17, Chicago, IL
60601

800.272.3900 | alz.org

tel:800.272.3900
[link removed]

© 2021 Alzheimer's Association. All rights
reserved. Alzheimer's Association is a not-for-profit 501(c)(3)
organization.

Contact Us
|
Privacy Policy
|
Unsubscribe

[link removed]
[link removed]
[link removed]



To unsubscribe from all future email, paste the following URL into your browser:
[link removed]